All the news articles and press releases in one place.


Date / Time Source Company % Chg Sector Market Cap Announcement
15Nov19 07:00 RNS AstraZeneca 1.31% Health £96,333m Qtrilmet approved in the EU for treatment of T2D
14Nov19 07:00 RNS AstraZeneca 1.31% Health £96,333m FDA accepts regulatory submission for selumetinib
12Nov19 07:00 RNS AstraZeneca 1.31% Health £96,333m Anifrolumab demonstrated superiority in TULIP 2
11Nov19 07:00 RNS AstraZeneca 1.31% Health £96,333m Roxadustat pooled analyses: no increased CV risk
08Nov19 07:00 RNS AstraZeneca 1.31% Health £96,333m Roxadustat significantly increased haemoglobin
06Nov19 14:10 RNS AstraZeneca 1.31% Health £96,333m Calquence data to show improved progression-free
01Nov19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
30Oct19 07:00 RNS AstraZeneca 1.31% Health £96,333m AstraZeneca divests rights to Seroquel and
28Oct19 15:31 RNS AstraZeneca 1.31% Health £96,333m Imfinzi and Imfinzi plus tremelimumab delayed
24Oct19 07:00 RNS AstraZeneca 1.31% Health £96,333m AstraZeneca year-to-date and Q3 2019 results
21Oct19 07:00 RNS AstraZeneca 1.31% Health £96,333m Farxiga approved in the US to reduce the risk of
17Oct19 07:00 RNS AstraZeneca 1.31% Health £96,333m Trastuzumab deruxtecan granted FDA Priority Review
04Oct19 15:04 RNS AstraZeneca 1.31% Health £96,333m Holding(s) in Company
04Oct19 15:00 RNS AstraZeneca 1.31% Health £96,333m Holding(s) in Company
04Oct19 07:00 RNS AstraZeneca 1.31% Health £96,333m Fasenra approved in the US for self-administration
03Oct19 16:00 RNS AstraZeneca 1.31% Health £96,333m Director Declaration
01Oct19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
01Oct19 07:05 RNS AstraZeneca 1.31% Health £96,333m AstraZeneca divests rights for Losec to Cheplaphar
01Oct19 07:00 RNS AstraZeneca 1.31% Health £96,333m Update on US regulatory review of PT010 in COPD
30Sep19 15:30 RNS AstraZeneca 1.31% Health £96,333m Lynparza more than doubled the time without
30Sep19 07:00 RNS AstraZeneca 1.31% Health £96,333m Lynparza improved the time women lived without
30Sep19 07:00 RNS AstraZeneca 1.31% Health £96,333m Tagrisso is the only 1st-line treatment for EGFR-
23Sep19 07:00 RNS AstraZeneca 1.31% Health £96,333m Qtrilmet recommended for approval in EU by CHMP
18Sep19 07:00 RNS AstraZeneca 1.31% Health £96,333m AstraZeneca amends collaboration with Ironwood
09Sep19 08:38 RNS AstraZeneca 1.31% Health £96,333m Imfinzi is first immunotherapy to show both
04Sep19 07:11 RNS AstraZeneca 1.31% Health £96,333m Tagrisso approved in China as a 1st-line treatment
02Sep19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
02Sep19 07:05 RNS AstraZeneca 1.31% Health £96,333m Brilinta reduced the risk of cardiovascular events
02Sep19 07:00 RNS AstraZeneca 1.31% Health £96,333m Detailed results from Phase III DAPA-HF trial
29Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Anifrolumab Phase III trial meets primary endpoint
28Aug19 07:05 RNS AstraZeneca 1.31% Health £96,333m Fasenra granted US Orphan Drug Designation for
28Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Breztri Aerosphere Phase III ETHOS trial met
22Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Roxadustat approved in China for the treatment of
22Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m AstraZeneca agrees to buy US FDA Priority Review
21Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Update on the Phase III NEPTUNE trial
20Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Farxiga met primary endpoint in landmark Phase III
19Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Directorate Change
14Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Lynparza Phase III PAOLA-1 trial met primary endpo
14Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Calquence granted US Breakthrough Therapy Designat
09Aug19 09:28 RNS AstraZeneca 1.31% Health £96,333m Amendment: Tagrisso significantly improves overall
09Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Tagrisso significantly improves overall survival
07Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Lynparza Phase III PROfound trial in HRR*
05Aug19 07:00 RNS AstraZeneca 1.31% Health £96,333m Forxiga label updated in the EU in type-2 diabetes
01Aug19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
25Jul19 07:00 RNS AstraZeneca 1.31% Health £96,333m AZN: H1 2019 Results
15Jul19 07:00 RNS AstraZeneca 1.31% Health £96,333m Update on US regulatory decision for Farxiga
12Jul19 07:00 RNS AstraZeneca 1.31% Health £96,333m Imfinzi granted US Orphan Drug Designation for
01Jul19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
01Jul19 07:00 RNS AstraZeneca 1.31% Health £96,333m Fasenra receives positive EU CHMP opinion for self
01Jul19 07:00 RNS AstraZeneca 1.31% Health £96,333m Forxiga receives positive EU CHMP opinion for
27Jun19 07:00 RNS AstraZeneca 1.31% Health £96,333m Imfinzi improves overall survival at interim
19Jun19 07:00 RNS AstraZeneca 1.31% Health £96,333m Bevespi Aerosphere approved by the Japanese
19Jun19 07:00 RNS AstraZeneca 1.31% Health £96,333m Lynparza approved in Japan for 1st-line
19Jun19 07:00 RNS AstraZeneca 1.31% Health £96,333m Breztri Aerosphere (PT010) approved in Japan for
18Jun19 07:00 RNS AstraZeneca 1.31% Health £96,333m Lynparza approved in the EU for 1st-line
17Jun19 07:00 RNS AstraZeneca 1.31% Health £96,333m Calquence significantly prolonged the time patient
12Jun19 16:45 RNS AstraZeneca 1.31% Health £96,333m Publication of a Prospectus
06Jun19 07:00 RNS AstraZeneca 1.31% Health £96,333m Calquence Phase III ELEVATE-TN trial met primary
05Jun19 12:36 EQS AstraZeneca 1.31% Health £96,333m Hardman & Co Research: AstraZeneca: Where has all the cash gone?
03Jun19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
03Jun19 07:00 RNS AstraZeneca 1.31% Health £96,333m Lynparza nearly doubled time patients lived with
10May19 07:00 RNS AstraZeneca 1.31% Health £96,333m Pooled analyses of the roxadustat global Phase III
08May19 14:00 RNS AstraZeneca 1.31% Health £96,333m Director/PDMR Shareholding
08May19 11:00 RNS AstraZeneca 1.31% Health £96,333m Director Declaration
08May19 07:00 RNS AstraZeneca 1.31% Health £96,333m Trastuzumab deruxtecan demonstrated clinically
07May19 07:00 RNS AstraZeneca 1.31% Health £96,333m Calquence PhIII ASCEND trial met primary endpoint
03May19 07:00 RNS AstraZeneca 1.31% Health £96,333m Qternmet XR approved in the US for type-2 diabetes
01May19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
01May19 12:00 RNS AstraZeneca 1.31% Health £96,333m Director/PDMR Shareholding
29Apr19 07:00 RNS AstraZeneca 1.31% Health £96,333m Lynparza receives positive EU CHMP opinion for 1st
26Apr19 17:45 RNS AstraZeneca 1.31% Health £96,333m Result of AGM
26Apr19 07:00 RNS AstraZeneca 1.31% Health £96,333m AZN: Q1 2019 Results
10Apr19 07:00 RNS AstraZeneca 1.31% Health £96,333m Lynparza approved in EU for the treatment of germl
09Apr19 16:10 EQS AstraZeneca 1.31% Health £96,333m Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales
04Apr19 13:30 RNS AstraZeneca 1.31% Health £96,333m Holding(s) in Company
03Apr19 10:00 RNS AstraZeneca 1.31% Health £96,333m Director/PDMR Shareholding
02Apr19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
01Apr19 18:00 RNS AstraZeneca 1.31% Health £96,333m Astrazeneca
01Apr19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
01Apr19 07:00 RNS AstraZeneca 1.31% Health £96,333m Selumetinib gets Breakthrough Therapy Designation
29Mar19 17:15 RNS AstraZeneca 1.31% Health £96,333m Results of Placing
29Mar19 07:00 RNS AstraZeneca 1.31% Health £96,333m AZ and Daiichi Sankyo enter collaboration in novel
29Mar19 07:00 RNS AstraZeneca 1.31% Health £96,333m Proposed placing of new ordinary shares
27Mar19 07:00 RNS AstraZeneca 1.31% Health £96,333m Forxiga approved in Japan for type-1 diabetes
25Mar19 07:00 RNS AstraZeneca 1.31% Health £96,333m Forxiga approved in Europe for type-1 diabetes
18Mar19 07:00 RNS AstraZeneca 1.31% Health £96,333m US FDA grants saracatinib ODD for IPF
14Mar19 12:00 RNS AstraZeneca 1.31% Health £96,333m Notice of AGM
12Mar19 12:00 RNS AstraZeneca 1.31% Health £96,333m Director/PDMR Shareholding
06Mar19 07:00 RNS AstraZeneca 1.31% Health £96,333m Filing of Form 20-F with SEC
05Mar19 11:00 RNS AstraZeneca 1.31% Health £96,333m Annual Financial Report
04Mar19 16:04 RNS AstraZeneca 1.31% Various Various Holding(s) in Company
01Mar19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
01Mar19 13:45 RNS AstraZeneca 1.31% Health £96,333m Lynparza receives positive EU CHMP opinion
26Feb19 07:00 RNS AstraZeneca 1.31% Health £96,333m Lynparza significantly delayed disease progression
25Feb19 07:00 RNS AstraZeneca 1.31% Health £96,333m Brilinta's PhIII THEMIS trial met primary endpoint
14Feb19 07:00 RNS AstraZeneca 1.31% Health £96,333m AstraZeneca Full-Year and Q4 2018 Results
06Feb19 07:00 RNS AstraZeneca 1.31% Health £96,333m US FDA grants Fasenra Orphan Drug Designation
05Feb19 07:05 RNS AstraZeneca 1.31% Health £96,333m US FDA grants Breakthrough Therapy Designation
05Feb19 07:00 RNS AstraZeneca 1.31% Health £96,333m EMA grants PRIME eligibility for MEDI8897
01Feb19 15:00 RNS AstraZeneca 1.31% Health £96,333m Total Voting Rights
Date / Time Source Company % Chg
15Nov19 07:00 RNS AstraZeneca 1.31%
Qtrilmet approved in the EU for treatment of T2D
14Nov19 07:00 RNS AstraZeneca 1.31%
FDA accepts regulatory submission for selumetinib
12Nov19 07:00 RNS AstraZeneca 1.31%
Anifrolumab demonstrated superiority in TULIP 2
11Nov19 07:00 RNS AstraZeneca 1.31%
Roxadustat pooled analyses: no increased CV risk
08Nov19 07:00 RNS AstraZeneca 1.31%
Roxadustat significantly increased haemoglobin
06Nov19 14:10 RNS AstraZeneca 1.31%
Calquence data to show improved progression-free
01Nov19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
30Oct19 07:00 RNS AstraZeneca 1.31%
AstraZeneca divests rights to Seroquel and
28Oct19 15:31 RNS AstraZeneca 1.31%
Imfinzi and Imfinzi plus tremelimumab delayed
24Oct19 07:00 RNS AstraZeneca 1.31%
AstraZeneca year-to-date and Q3 2019 results
21Oct19 07:00 RNS AstraZeneca 1.31%
Farxiga approved in the US to reduce the risk of
17Oct19 07:00 RNS AstraZeneca 1.31%
Trastuzumab deruxtecan granted FDA Priority Review
04Oct19 15:04 RNS AstraZeneca 1.31%
Holding(s) in Company
04Oct19 15:00 RNS AstraZeneca 1.31%
Holding(s) in Company
04Oct19 07:00 RNS AstraZeneca 1.31%
Fasenra approved in the US for self-administration
03Oct19 16:00 RNS AstraZeneca 1.31%
Director Declaration
01Oct19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
01Oct19 07:05 RNS AstraZeneca 1.31%
AstraZeneca divests rights for Losec to Cheplaphar
01Oct19 07:00 RNS AstraZeneca 1.31%
Update on US regulatory review of PT010 in COPD
30Sep19 15:30 RNS AstraZeneca 1.31%
Lynparza more than doubled the time without
30Sep19 07:00 RNS AstraZeneca 1.31%
Lynparza improved the time women lived without
30Sep19 07:00 RNS AstraZeneca 1.31%
Tagrisso is the only 1st-line treatment for EGFR-
23Sep19 07:00 RNS AstraZeneca 1.31%
Qtrilmet recommended for approval in EU by CHMP
18Sep19 07:00 RNS AstraZeneca 1.31%
AstraZeneca amends collaboration with Ironwood
09Sep19 08:38 RNS AstraZeneca 1.31%
Imfinzi is first immunotherapy to show both
04Sep19 07:11 RNS AstraZeneca 1.31%
Tagrisso approved in China as a 1st-line treatment
02Sep19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
02Sep19 07:05 RNS AstraZeneca 1.31%
Brilinta reduced the risk of cardiovascular events
02Sep19 07:00 RNS AstraZeneca 1.31%
Detailed results from Phase III DAPA-HF trial
29Aug19 07:00 RNS AstraZeneca 1.31%
Anifrolumab Phase III trial meets primary endpoint
28Aug19 07:05 RNS AstraZeneca 1.31%
Fasenra granted US Orphan Drug Designation for
28Aug19 07:00 RNS AstraZeneca 1.31%
Breztri Aerosphere Phase III ETHOS trial met
22Aug19 07:00 RNS AstraZeneca 1.31%
Roxadustat approved in China for the treatment of
22Aug19 07:00 RNS AstraZeneca 1.31%
AstraZeneca agrees to buy US FDA Priority Review
21Aug19 07:00 RNS AstraZeneca 1.31%
Update on the Phase III NEPTUNE trial
20Aug19 07:00 RNS AstraZeneca 1.31%
Farxiga met primary endpoint in landmark Phase III
19Aug19 07:00 RNS AstraZeneca 1.31%
Directorate Change
14Aug19 07:00 RNS AstraZeneca 1.31%
Lynparza Phase III PAOLA-1 trial met primary endpo
14Aug19 07:00 RNS AstraZeneca 1.31%
Calquence granted US Breakthrough Therapy Designat
09Aug19 09:28 RNS AstraZeneca 1.31%
Amendment: Tagrisso significantly improves overall
09Aug19 07:00 RNS AstraZeneca 1.31%
Tagrisso significantly improves overall survival
07Aug19 07:00 RNS AstraZeneca 1.31%
Lynparza Phase III PROfound trial in HRR*
05Aug19 07:00 RNS AstraZeneca 1.31%
Forxiga label updated in the EU in type-2 diabetes
01Aug19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
25Jul19 07:00 RNS AstraZeneca 1.31%
AZN: H1 2019 Results
15Jul19 07:00 RNS AstraZeneca 1.31%
Update on US regulatory decision for Farxiga
12Jul19 07:00 RNS AstraZeneca 1.31%
Imfinzi granted US Orphan Drug Designation for
01Jul19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
01Jul19 07:00 RNS AstraZeneca 1.31%
Fasenra receives positive EU CHMP opinion for self
01Jul19 07:00 RNS AstraZeneca 1.31%
Forxiga receives positive EU CHMP opinion for
27Jun19 07:00 RNS AstraZeneca 1.31%
Imfinzi improves overall survival at interim
19Jun19 07:00 RNS AstraZeneca 1.31%
Bevespi Aerosphere approved by the Japanese
19Jun19 07:00 RNS AstraZeneca 1.31%
Lynparza approved in Japan for 1st-line
19Jun19 07:00 RNS AstraZeneca 1.31%
Breztri Aerosphere (PT010) approved in Japan for
18Jun19 07:00 RNS AstraZeneca 1.31%
Lynparza approved in the EU for 1st-line
17Jun19 07:00 RNS AstraZeneca 1.31%
Calquence significantly prolonged the time patient
12Jun19 16:45 RNS AstraZeneca 1.31%
Publication of a Prospectus
06Jun19 07:00 RNS AstraZeneca 1.31%
Calquence Phase III ELEVATE-TN trial met primary
05Jun19 12:36 EQS AstraZeneca 1.31%
Hardman & Co Research: AstraZeneca: Where has all the cash gone?
03Jun19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
03Jun19 07:00 RNS AstraZeneca 1.31%
Lynparza nearly doubled time patients lived with
10May19 07:00 RNS AstraZeneca 1.31%
Pooled analyses of the roxadustat global Phase III
08May19 14:00 RNS AstraZeneca 1.31%
Director/PDMR Shareholding
08May19 11:00 RNS AstraZeneca 1.31%
Director Declaration
08May19 07:00 RNS AstraZeneca 1.31%
Trastuzumab deruxtecan demonstrated clinically
07May19 07:00 RNS AstraZeneca 1.31%
Calquence PhIII ASCEND trial met primary endpoint
03May19 07:00 RNS AstraZeneca 1.31%
Qternmet XR approved in the US for type-2 diabetes
01May19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
01May19 12:00 RNS AstraZeneca 1.31%
Director/PDMR Shareholding
29Apr19 07:00 RNS AstraZeneca 1.31%
Lynparza receives positive EU CHMP opinion for 1st
26Apr19 17:45 RNS AstraZeneca 1.31%
Result of AGM
26Apr19 07:00 RNS AstraZeneca 1.31%
AZN: Q1 2019 Results
10Apr19 07:00 RNS AstraZeneca 1.31%
Lynparza approved in EU for the treatment of germl
09Apr19 16:10 EQS AstraZeneca 1.31%
Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales
04Apr19 13:30 RNS AstraZeneca 1.31%
Holding(s) in Company
03Apr19 10:00 RNS AstraZeneca 1.31%
Director/PDMR Shareholding
02Apr19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
01Apr19 18:00 RNS AstraZeneca 1.31%
Astrazeneca
01Apr19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
01Apr19 07:00 RNS AstraZeneca 1.31%
Selumetinib gets Breakthrough Therapy Designation
29Mar19 17:15 RNS AstraZeneca 1.31%
Results of Placing
29Mar19 07:00 RNS AstraZeneca 1.31%
AZ and Daiichi Sankyo enter collaboration in novel
29Mar19 07:00 RNS AstraZeneca 1.31%
Proposed placing of new ordinary shares
27Mar19 07:00 RNS AstraZeneca 1.31%
Forxiga approved in Japan for type-1 diabetes
25Mar19 07:00 RNS AstraZeneca 1.31%
Forxiga approved in Europe for type-1 diabetes
18Mar19 07:00 RNS AstraZeneca 1.31%
US FDA grants saracatinib ODD for IPF
14Mar19 12:00 RNS AstraZeneca 1.31%
Notice of AGM
12Mar19 12:00 RNS AstraZeneca 1.31%
Director/PDMR Shareholding
06Mar19 07:00 RNS AstraZeneca 1.31%
Filing of Form 20-F with SEC
05Mar19 11:00 RNS AstraZeneca 1.31%
Annual Financial Report
04Mar19 16:04 RNS AstraZeneca 1.31%
Holding(s) in Company
01Mar19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
01Mar19 13:45 RNS AstraZeneca 1.31%
Lynparza receives positive EU CHMP opinion
26Feb19 07:00 RNS AstraZeneca 1.31%
Lynparza significantly delayed disease progression
25Feb19 07:00 RNS AstraZeneca 1.31%
Brilinta's PhIII THEMIS trial met primary endpoint
14Feb19 07:00 RNS AstraZeneca 1.31%
AstraZeneca Full-Year and Q4 2018 Results
06Feb19 07:00 RNS AstraZeneca 1.31%
US FDA grants Fasenra Orphan Drug Designation
05Feb19 07:05 RNS AstraZeneca 1.31%
US FDA grants Breakthrough Therapy Designation
05Feb19 07:00 RNS AstraZeneca 1.31%
EMA grants PRIME eligibility for MEDI8897
01Feb19 15:00 RNS AstraZeneca 1.31%
Total Voting Rights
Date / Time Company % Chg
15Nov19 07:00 AstraZeneca 1.31%
Qtrilmet approved in the EU for treatment of T2D
14Nov19 07:00 AstraZeneca 1.31%
FDA accepts regulatory submission for selumetinib
12Nov19 07:00 AstraZeneca 1.31%
Anifrolumab demonstrated superiority in TULIP 2
11Nov19 07:00 AstraZeneca 1.31%
Roxadustat pooled analyses: no increased CV risk
08Nov19 07:00 AstraZeneca 1.31%
Roxadustat significantly increased haemoglobin
06Nov19 14:10 AstraZeneca 1.31%
Calquence data to show improved progression-free
01Nov19 15:00 AstraZeneca 1.31%
Total Voting Rights
30Oct19 07:00 AstraZeneca 1.31%
AstraZeneca divests rights to Seroquel and
28Oct19 15:31 AstraZeneca 1.31%
Imfinzi and Imfinzi plus tremelimumab delayed
24Oct19 07:00 AstraZeneca 1.31%
AstraZeneca year-to-date and Q3 2019 results
21Oct19 07:00 AstraZeneca 1.31%
Farxiga approved in the US to reduce the risk of
17Oct19 07:00 AstraZeneca 1.31%
Trastuzumab deruxtecan granted FDA Priority Review
04Oct19 15:04 AstraZeneca 1.31%
Holding(s) in Company
04Oct19 15:00 AstraZeneca 1.31%
Holding(s) in Company
04Oct19 07:00 AstraZeneca 1.31%
Fasenra approved in the US for self-administration
03Oct19 16:00 AstraZeneca 1.31%
Director Declaration
01Oct19 15:00 AstraZeneca 1.31%
Total Voting Rights
01Oct19 07:05 AstraZeneca 1.31%
AstraZeneca divests rights for Losec to Cheplaphar
01Oct19 07:00 AstraZeneca 1.31%
Update on US regulatory review of PT010 in COPD
30Sep19 15:30 AstraZeneca 1.31%
Lynparza more than doubled the time without
30Sep19 07:00 AstraZeneca 1.31%
Lynparza improved the time women lived without
30Sep19 07:00 AstraZeneca 1.31%
Tagrisso is the only 1st-line treatment for EGFR-
23Sep19 07:00 AstraZeneca 1.31%
Qtrilmet recommended for approval in EU by CHMP
18Sep19 07:00 AstraZeneca 1.31%
AstraZeneca amends collaboration with Ironwood
09Sep19 08:38 AstraZeneca 1.31%
Imfinzi is first immunotherapy to show both
04Sep19 07:11 AstraZeneca 1.31%
Tagrisso approved in China as a 1st-line treatment
02Sep19 15:00 AstraZeneca 1.31%
Total Voting Rights
02Sep19 07:05 AstraZeneca 1.31%
Brilinta reduced the risk of cardiovascular events
02Sep19 07:00 AstraZeneca 1.31%
Detailed results from Phase III DAPA-HF trial
29Aug19 07:00 AstraZeneca 1.31%
Anifrolumab Phase III trial meets primary endpoint
28Aug19 07:05 AstraZeneca 1.31%
Fasenra granted US Orphan Drug Designation for
28Aug19 07:00 AstraZeneca 1.31%
Breztri Aerosphere Phase III ETHOS trial met
22Aug19 07:00 AstraZeneca 1.31%
Roxadustat approved in China for the treatment of
22Aug19 07:00 AstraZeneca 1.31%
AstraZeneca agrees to buy US FDA Priority Review
21Aug19 07:00 AstraZeneca 1.31%
Update on the Phase III NEPTUNE trial
20Aug19 07:00 AstraZeneca 1.31%
Farxiga met primary endpoint in landmark Phase III
19Aug19 07:00 AstraZeneca 1.31%
Directorate Change
14Aug19 07:00 AstraZeneca 1.31%
Lynparza Phase III PAOLA-1 trial met primary endpo
14Aug19 07:00 AstraZeneca 1.31%
Calquence granted US Breakthrough Therapy Designat
09Aug19 09:28 AstraZeneca 1.31%
Amendment: Tagrisso significantly improves overall
09Aug19 07:00 AstraZeneca 1.31%
Tagrisso significantly improves overall survival
07Aug19 07:00 AstraZeneca 1.31%
Lynparza Phase III PROfound trial in HRR*
05Aug19 07:00 AstraZeneca 1.31%
Forxiga label updated in the EU in type-2 diabetes
01Aug19 15:00 AstraZeneca 1.31%
Total Voting Rights
25Jul19 07:00 AstraZeneca 1.31%
AZN: H1 2019 Results
15Jul19 07:00 AstraZeneca 1.31%
Update on US regulatory decision for Farxiga
12Jul19 07:00 AstraZeneca 1.31%
Imfinzi granted US Orphan Drug Designation for
01Jul19 15:00 AstraZeneca 1.31%
Total Voting Rights
01Jul19 07:00 AstraZeneca 1.31%
Fasenra receives positive EU CHMP opinion for self
01Jul19 07:00 AstraZeneca 1.31%
Forxiga receives positive EU CHMP opinion for
27Jun19 07:00 AstraZeneca 1.31%
Imfinzi improves overall survival at interim
19Jun19 07:00 AstraZeneca 1.31%
Bevespi Aerosphere approved by the Japanese
19Jun19 07:00 AstraZeneca 1.31%
Lynparza approved in Japan for 1st-line
19Jun19 07:00 AstraZeneca 1.31%
Breztri Aerosphere (PT010) approved in Japan for
18Jun19 07:00 AstraZeneca 1.31%
Lynparza approved in the EU for 1st-line
17Jun19 07:00 AstraZeneca 1.31%
Calquence significantly prolonged the time patient
12Jun19 16:45 AstraZeneca 1.31%
Publication of a Prospectus
06Jun19 07:00 AstraZeneca 1.31%
Calquence Phase III ELEVATE-TN trial met primary
05Jun19 12:36 AstraZeneca 1.31%
Hardman & Co Research: AstraZeneca: Where has all the cash gone?
03Jun19 15:00 AstraZeneca 1.31%
Total Voting Rights
03Jun19 07:00 AstraZeneca 1.31%
Lynparza nearly doubled time patients lived with
10May19 07:00 AstraZeneca 1.31%
Pooled analyses of the roxadustat global Phase III
08May19 14:00 AstraZeneca 1.31%
Director/PDMR Shareholding
08May19 11:00 AstraZeneca 1.31%
Director Declaration
08May19 07:00 AstraZeneca 1.31%
Trastuzumab deruxtecan demonstrated clinically
07May19 07:00 AstraZeneca 1.31%
Calquence PhIII ASCEND trial met primary endpoint
03May19 07:00 AstraZeneca 1.31%
Qternmet XR approved in the US for type-2 diabetes
01May19 15:00 AstraZeneca 1.31%
Total Voting Rights
01May19 12:00 AstraZeneca 1.31%
Director/PDMR Shareholding
29Apr19 07:00 AstraZeneca 1.31%
Lynparza receives positive EU CHMP opinion for 1st
26Apr19 17:45 AstraZeneca 1.31%
Result of AGM
26Apr19 07:00 AstraZeneca 1.31%
AZN: Q1 2019 Results
10Apr19 07:00 AstraZeneca 1.31%
Lynparza approved in EU for the treatment of germl
09Apr19 16:10 AstraZeneca 1.31%
Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales
04Apr19 13:30 AstraZeneca 1.31%
Holding(s) in Company
03Apr19 10:00 AstraZeneca 1.31%
Director/PDMR Shareholding
02Apr19 15:00 AstraZeneca 1.31%
Total Voting Rights
01Apr19 18:00 AstraZeneca 1.31%
Astrazeneca
01Apr19 15:00 AstraZeneca 1.31%
Total Voting Rights
01Apr19 07:00 AstraZeneca 1.31%
Selumetinib gets Breakthrough Therapy Designation
29Mar19 17:15 AstraZeneca 1.31%
Results of Placing
29Mar19 07:00 AstraZeneca 1.31%
AZ and Daiichi Sankyo enter collaboration in novel
29Mar19 07:00 AstraZeneca 1.31%
Proposed placing of new ordinary shares
27Mar19 07:00 AstraZeneca 1.31%
Forxiga approved in Japan for type-1 diabetes
25Mar19 07:00 AstraZeneca 1.31%
Forxiga approved in Europe for type-1 diabetes
18Mar19 07:00 AstraZeneca 1.31%
US FDA grants saracatinib ODD for IPF
14Mar19 12:00 AstraZeneca 1.31%
Notice of AGM
12Mar19 12:00 AstraZeneca 1.31%
Director/PDMR Shareholding
06Mar19 07:00 AstraZeneca 1.31%
Filing of Form 20-F with SEC
05Mar19 11:00 AstraZeneca 1.31%
Annual Financial Report
04Mar19 16:04 AZN LSE,CIR LSE 1.31%
Holding(s) in Company
01Mar19 15:00 AstraZeneca 1.31%
Total Voting Rights
01Mar19 13:45 AstraZeneca 1.31%
Lynparza receives positive EU CHMP opinion
26Feb19 07:00 AstraZeneca 1.31%
Lynparza significantly delayed disease progression
25Feb19 07:00 AstraZeneca 1.31%
Brilinta's PhIII THEMIS trial met primary endpoint
14Feb19 07:00 AstraZeneca 1.31%
AstraZeneca Full-Year and Q4 2018 Results
06Feb19 07:00 AstraZeneca 1.31%
US FDA grants Fasenra Orphan Drug Designation
05Feb19 07:05 AstraZeneca 1.31%
US FDA grants Breakthrough Therapy Designation
05Feb19 07:00 AstraZeneca 1.31%
EMA grants PRIME eligibility for MEDI8897
01Feb19 15:00 AstraZeneca 1.31%
Total Voting Rights